APX-115

DRUG2 trials

Sponsors

Aptabio Therapeutics, Inc.

Conditions

COVID-19Diabetes Mellitus, Type 2Diabetic NephropathiesNephropathy, Diabetic

Phase 2

Safety, Tolerability and Renal Effects of APX-115 in Subjects With Type 2 Diabetes and Nephropathy

CompletedNCT04534439

Aptabio Therapeutics, Inc.Diabetes Mellitus, Type 2, Diabetic Nephropathies, Nephropathy, Diabetic

Start: 2020-08-24End: 2021-08-23Updated: 2021-08-25

A Phase 2 Study of APX-115 in Hospitalized Patients With Confirmed Mild to Moderate COVID-19.

TerminatedNCT04880109

Aptabio Therapeutics, Inc.COVID-19

Start: 2021-10-20End: 2022-04-28Updated: 2026-06-10